Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04956965
Other study ID # 19_RIPH3-03
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date August 2021
Est. completion date May 2022

Study information

Verified date July 2021
Source University Hospital Center of Martinique
Contact Jocelyne CRASPAG, MSc
Phone +596596592698
Email jocelyne.craspag@chu-martinique.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Amyloid heart disease is an accumulation of fibrillar proteins in the extracellular sector of the heart. Identified on echocardiography as Ventricular hypertrophy. The investigation of a Left Ventricular hypertrophy (LVH) is the most frequent discovery circumstance of amyloid heart disease. Pathophysiological mechanisms poorly understood, resulting in late diagnosis. Transthyretin amyloid heart disease (CATTR) is the most common form of cardiac amyloidosis in the West Indies due to an abnormally high frequency of the Val122Ile and Val107Ile mutations of the transthyretin gene in this population. Val122Ile and Val107Ile mutated-transthyretin are the substitution of valine for isoleucine at codon 122 of the TTR gene ( V122I) and at codon 107 of the TTR gene (V107I). Complications of CATTR are functional changes in heart cells or even death due to mechanical abnormalities (loss of contractility and increased wall stiffness cardiac arousal and conduction disturbances). These disorders result from an electrical abnormality of the heart the reason why the cardiologist performs preventive performance of electrophysiological explorations with EnSite Precision™. It's a registration system used to detect foci of necrosis within the myocardium. Amyloid deposits are areas devoid of electrical activity. Do they detectable by the EnSite Precision™ recording system ?


Description:

Transthyretin's amyloid heart disease (CATTR) is a rare disease whose frequency is high in the Caribbean's due to a high frequency of Val122Ile, an amyloidosis prone mutation in the Transthyretin gene. The Val122Ile variant might be present in 15 to 20 000 subjects in Martinique, placing them at high risk to develop the CATTR. CATTR results from the accumulation of amyloid deposits between the intercellular spans, resulting in mechanical cardiac abnormalities, but also in latent excitation or conduction defects: atrial and ventricular hyperexcitability, bundle branch blocks, atrio-ventricular blocks. These abnormalities require systematic electrophysiological studies and if necessary, antiarrythmic medications or pacemaker placement. Electro-mapping of the cardiac chambers offers high-resolution three-dimensional maps of cardiac electrical activity which has been used recently to detect focal myocardial infarction. This anatomo-functional imaging, used only once in cardiac amyloidosis, showed a correlation between areas of low voltage of the left atrial myocardium and areas of late gadolinium enhancement, a marker of amyloidosis deposit, found in cardiac MRI.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 24
Est. completion date May 2022
Est. primary completion date August 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Controls: - Aged 18 and more - Have had an echocardiogram within 6 months prior to inclusion - Have had a cardiac Holter in the 6 months prior to inclusion. - Informed Consent given Cases : - Aged 18 and over - Presence of cardiac amyloidosis with Transthyretin - Have had an echocardiogram within 6 months prior to inclusion - Have had a cardiac Holter monitoring in the 6 months prior to inclusion. - Informed Consent given Exclusion Criteria: Controls - Known case of amyloidosis in the immediate family - Patient known to have amyloidosis - Left ventricular wall thickness greater than or equal to 14 mm - Hyperechogenicity of the left ventricular walls - Cardiac disease which may affect electro-anatomic mapping: Right ventricular dysplasia, myocardial infarction, congenital heart disease. - Contraindication such as pregnancy to radiological exams - Presence of an anomaly of the vena cava - Presence of intracavitary thrombus at cardiac echocardiography - Patients with a pacemaker Cases - Cardiac disease which may affect electro-anatomic mapping: Right ventricular dysplasia, myocardial infarction, congenital heart disease. - Contraindication such as pregnancy to radiological exams - Presence of an anomaly of the vena cava - Presence of intracavitary thrombus at cardiac echocardiography

Study Design


Intervention

Radiation:
Cardiac electro-mapping
Perform an high-resolution three-dimensional maps of cardiac electrical activity using EnSite Precision system.

Locations

Country Name City State
Martinique Centre Hospitalier Universitaire de Fort-de-France Fort-de-France

Sponsors (2)

Lead Sponsor Collaborator
University Hospital Center of Martinique GIRCI SOHO

Country where clinical trial is conducted

Martinique, 

References & Publications (4)

Khairy LT, Barin R, Demonière F, Villemaire C, Billo MJ, Tardif JC, Macle L, Khairy P. Heart Rate Response in Spectators of the Montreal Canadiens Hockey Team. Can J Cardiol. 2017 Dec;33(12):1633-1638. doi: 10.1016/j.cjca.2017.08.002. Epub 2017 Oct 5. — View Citation

Oliveira Da Silva L, Fabre J, Monfort A, Villeret J, Citony I, Cohen-Tenoudji P, Lebbadi M, Martin D, Molinié V, Inamo J. 'Green Apple' Heart Failure. West Indian Med J. 2014 Jul 3;63(6):673-5. doi: 10.7727/wimj.2013.255. Epub 2014 Jun 25. — View Citation

Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, Habibi A, Bennani S, Savale L, Adnot S, Maitre B, Yaïci A, Hajji L, O'Callaghan DS, Clerson P, Girot R, Galacteros F, Simonneau G. A hemodynamic study of pulmonary hypertension in sickle cell diseas — View Citation

Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, Macle L, Daoud EG, Calkins H, Hall B, Reddy V, Augello G, Reynolds MR, Vinekar C, Liu CY, Berry SM, Berry DA; ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of zones with abnormal electrical activity Percentage of subject with at least one area of electrical inactivity (<0.1 mV) or at least one area of continuous low-voltage activity 1 month
Secondary Characteristics of zones with electrical inactivity Number of areas of electrical inactivity (<0.1 mV) 1 month
Secondary Zones with electrical inactivity Area of surface of electrical inactivity (<0.1 mV) 1 month
Secondary Characteristics of zones with abnormal electrical activity Number of areas of continuous low voltage activity 1 month
Secondary Zones with abnormal electrical activity Surface of areas of continuous low voltage activity 1 month
Secondary Compare electrical activity anomaly to total longitudinal strain on cardiac ultrasound Number of areas of electrical inactivity vs. total longitudinal strain on cardiac ultrasound. 1 month
Secondary Electrical activity anomaly and total longitudinal strain on cardiac ultrasound Number of areas of continuous low voltage activity vs. Total longitudinal strain on cardiac ultrasound. 1 month
Secondary Compare electrical activity anomaly (surface) to total longitudinal strain on cardiac ultrasound Surface of areas of electrical inactivity vs. Total longitudinal strain on cardiac ultrasound. 1 month
Secondary Electrical activity anomaly (continuous low voltage activity) and total longitudinal strain on cardiac ultrasound Surface of areas of continuous low voltage activity vs. Total longitudinal strain on cardiac ultrasound. 1 month
Secondary Compare electrical activity anomaly to Brain Natriuretic Peptide (BNP) value Number of areas of electrical inactivity vs. BNP value. 1 month
Secondary Electrical activity and Brain Natriuretic Peptide (BNP) value Number of areas of continuous low voltage activity vs. BNP value. 1 month
Secondary Compare electrical activity anomaly (surface) to Brain Natriuretic Peptide (BNP) value Surface of areas of electrical inactivity vs. BNP value. 1 month
Secondary Electrical activity anomaly (continuous low voltage activity) and Brain Natriuretic Peptide (BNP) value Surface of areas of continuous low voltage activity vs. BNP value. 1 month
Secondary Compare electrical activity anomaly to the presence of severe ventricular arrhythmia Number of areas of electrical inactivity vs. the presence of severe ventricular arrhythmia. 1 month
Secondary Electrical activity anomaly and presence of severe ventricular arrhythmia Number of areas of continuous low voltage activity vs. the presence of severe ventricular arrhythmia. 1 month
Secondary Compare electrical activity anomaly (surface) to the presence of severe ventricular arrhythmia Surface of areas of electrical inactivity vs. the presence of severe ventricular arrhythmia. 1 month
Secondary Electrical activity anomaly (continuous low voltage activity) and presence of severe ventricular arrhythmia Surface of areas of continuous low voltage activity vs. the presence of severe ventricular arrhythmia. 1 month
Secondary Compare electrical activity anomaly and to the presence of an atrial arrythmia Number of areas of electrical inactivity vs. the presence of an atrial fibrillation load. 1 month
Secondary Electrical activity anomaly and presence of an atrial arrythmia Number of areas of continuous low voltage activity vs. the presence of an atrial fibrillation load. 1 month
Secondary Compare electrical activity anomaly (surface) to the presence of an atrial arrythmia Surface of areas of electrical inactivity vs. the presence of an atrial fibrillation load. 1 month
Secondary Electrical activity anomaly (continuous low voltage activity) and presence of an atrial arrythmia Surface of areas of continuous low voltage activity vs. the presence of an atrial fibrillation load. 1 month
See also
  Status Clinical Trial Phase
Recruiting NCT05490303 - HeartGuide: Preliminary Study N/A
Completed NCT05070819 - Atrial Natriuretic Peptide in Assessing Fluid Status N/A
Not yet recruiting NCT04511403 - Prevalence of Oral Mucosal Alterations In a Sample of Egyptian Patients With Cardiovascular Diseases: A Hospital- Based Cross-Sectional Study
Not yet recruiting NCT04538469 - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Completed NCT02697760 - The CZT Dynamic Myocardial Perfusion Imaging
Terminated NCT05157568 - Pilot Randomized Clinical Trial of Live-streamed Cardiovascular Rehabilitation N/A
Not yet recruiting NCT04160845 - Non-invasive Forehead Skin Temperature in Cardiac Surgery
Completed NCT04500912 - Comparison of the Supraflex Cruz 60 Micron Versus the Ultimaster Tansei 80 Micron in HBR PCI Population N/A
Recruiting NCT06154473 - Assessment of Patients Undergoing Cardiac Surgery and Admitted to the Intensive Care Unit
Not yet recruiting NCT05877755 - Validation of Multi-contrast, High-resolution Cardiac Magnetic Resonance Imaging N/A
Completed NCT03394859 - Electronic Medical Records and Genomics (eMERGE) Phase III
Recruiting NCT05055830 - Opportunistic PK/PD Trial in Critically Ill Children (OPTIC)
Recruiting NCT04374799 - Heparin vs Placebo for Cardiac Catheterization Phase 3
Completed NCT03174106 - Longterm Follow-up of Cardiac Patients With an Smartphone-Application N/A
Recruiting NCT05531253 - Respired Gases in Patients Post Cardiac Surgery
Recruiting NCT04609228 - Cardiac Surgery Outcomes in Blood-transfusion Acceptors and no Acceptors
Recruiting NCT06149143 - Cardiac Performance System Data Collection Study - Minnesota
Recruiting NCT05725655 - Hot Water Immersion After Myocardial Infarction N/A
Recruiting NCT06073509 - Atrial Fibrillation and Other Cardiac Arrhythmias and Diseases After Radiotherapy for Breast Cancer : Watch Your HeaRT
Enrolling by invitation NCT04886934 - Temporary Epicardial Pace Wire With Integrated Sensor for Continuous Postoperative Monitoring of Myocardial Function N/A